健之佳股价震荡下行，机构评级中性，关注业务布局与股东增持

Group 1 - The stock price of Jianzhijia (605266) has shown a downward trend over the past week, with a cumulative decline of 0.68% and a fluctuation of 2.38%, reaching a high of 20.94 yuan on February 11 and a low of 20.45 yuan on February 13 [1] - On February 13, the trading volume decreased to 17.51 million yuan, with a turnover rate of 0.55%, indicating a decline compared to previous trading days. The net outflow of main funds in the past five days was approximately 2.418 million yuan, with a single-day net outflow of 263,100 yuan on February 13, reflecting low control by main funds and a dispersed chip distribution [1] - The stock price is currently close to the lower Bollinger Band support level of 19.84 yuan, with the MACD indicator showing signs of weakening bullish momentum and the KDJ value in a neutral range, indicating the need to monitor the effectiveness of the support level in the short term [1] Group 2 - As of February 14, the market attention on Jianzhijia is neutral, with institutional ratings primarily being neutral. The comprehensive target price is set at 22.50 yuan, indicating a potential upside of 14.85% compared to the latest price of 20.47 yuan [2] - Institutions forecast a net profit growth of 33.25% year-on-year for 2025 and a growth rate of 31.86% for 2026, mainly benefiting from the steady expansion of the pharmaceutical retail business and optimized cost control. However, it is noted that the fund holding ratio has decreased by 0.84 percentage points compared to the previous period, and the frequency of institutional research is low, reflecting limited capital participation [2] Group 3 - Recently, there have been no new major announcements from the company, but the market continues to focus on its long-term business layout, including the resilience of growth in the pharmaceutical e-commerce sector through its own platform and third-party channels (such as Meituan and JD.com) [3] - The family doctor signing service has covered over 8,000 people, with policy guidance favoring business extension [3] - The shareholding increase plan announced in January 2026, where Yunnan Xiangqun intends to invest 50 million yuan to increase holdings, is still in the execution period, which may support market sentiment [3]